Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Clinical Challenges in Heart Failure Management: 2nd Edition
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Challenges in Heart Failure Management: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 20 July 2026 | Viewed by 1011

Special Issue Editors

Dr. Paolo Severino

E-Mail Website
Guest Editor
Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Umberto I Hospital, Sapienza University of Rome, 00161 Roma, Italy
Interests: heart failure; ischemic heart disease; chronic heart failure; myocardial infarction; clinical cardiology; acute heart failure
Special Issues, Collections and Topics in MDPI journals
Dr. Gaetano M. Ruocco

E-Mail Website
Guest Editor
Cardiology Unit, "Buon Consiglio Hospital" Fatebenefratelli, Naples, Italy
Interests: acute heart failure; heart failure; clinical cardiology; myocardial infarction; chronic heart failure; echocardiography; cardiac function; cardiovascular medicine; cardiac imaging; internal medicine
Special Issues, Collections and Topics in MDPI journals
Dr. Andrea D'Amato

E-Mail Website
Guest Editor
1. Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155-00161 Rome, Italy
2. Cardiology Unit, Fabrizio Spaziani Hospital, Frosinone, Italy
Interests: acute heart failure; chronic heart failure; biomarkers; pharmacology; coronary microvascular dysfunction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure (HF) is a pandemic of the third millennium, accounting for high rates of mortality and hospitalizations. The HF burden has exposed cardiologists and hospitals to an increasing number of patients requiring treatment. For this reason, an improved approach to HF is required. The introduction of new treatment strategies, such as guanylate cyclase stimulators and myosin activators, is opening up new possibilities for HF patients to avoid adverse events. Moreover, the results of recent SGLT2i trials have opened up new treatment possibilities for HF patients with preserved ejection fraction. Besides pharmacological treatment, interesting results have been observed regarding the non-pharmacological treatment for HF, such as cardiac contractility modulation (CCM) in patients with refractory symptoms, which reduces the number of HF and CV deaths. Moreover, the COVID era showed the potential of telemedicine in HF. In conclusion, a tailored approach to HF patients is needed in order to improve the quality of life of patients.

This Special Issue will focus on new challenges in heart failure management. Original articles and reviews of the current literature on this topic will be taken into account. The Special Issue will focus on diagnostic, prognostic, and therapeutic innovations with the aim of sharing clinical experiences to improve HF patients’ management.

Dr. Paolo Severino
Dr. Gaetano M. Ruocco
Dr. Andrea D'Amato
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute heart failure
  • chronic heart failure
  • inotropic support
  • left ventricular assist device
  • cardiac contractility modulation
  • guanylate cyclase stimulators
  • quality of life
  • telemedicine
  • palliative care

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 529 KB  
Article
Sex-Based Differences in Management and Outcomes of Patients Admitted or Transferred to Advanced Therapy Centers for Heart Failure
by Ilya Kim, Oluwatoba Akinleye, Jaya Kanduri, Pritha Subramanyam, Udhay Krishnan, Ilhwan Yeo, Jim Cheung, Luke Kim and Daniel Yang Lu
J. Clin. Med. 2026, 15(7), 2776; https://doi.org/10.3390/jcm15072776 - 7 Apr 2026
Viewed by 308
Abstract
Background: Heart failure (HF) is a major public health challenge. Management at or transfer to advanced therapy centers (ATCs) is linked to greater procedural use and better outcomes for HF, however there is little data on the impact of patient sex on access [...] Read more.
Background: Heart failure (HF) is a major public health challenge. Management at or transfer to advanced therapy centers (ATCs) is linked to greater procedural use and better outcomes for HF, however there is little data on the impact of patient sex on access to ATCs and transfer patterns. We evaluated sex-based differences in HF management and outcomes during admissions across center types and transfer status. Method: Adult HF admissions were identified in the 2016–19 Nationwide Readmissions Database. Centers performing ≥1 heart transplant or LVAD were classified as ATCs. Patients were stratified by sex and center type: (A) non-ATC admission, (B) ATC admission, (C) transfer to ATC. Multivariable regression adjusted for comorbidities and HF decompensations. Results: Among 2,872,268 weighted HF admissions (51.3% male), females were older, while males had more HF decompensations (cardiogenic shock, ventricular arrhythmias, mechanical ventilation, AKI). Females comprised only 39.6% of all transfers to ATCs (0.4% vs. 0.6%, OR 0.69, p < 0.001) and had a lower unadjusted mortality (2.6% vs. 2.8%, p < 0.001); however, rates of transfer and mortality were similar between sexes when adjusted for comorbidities and HF decompensations. Female patients were significantly less likely to receive invasive procedures (CRT/ICD, PCI, right heart catheterization, CABG, temporary mechanical support, ECMO, LVAD or heart transplant) across all hospital types and transfers. This disparity in procedural utilization persisted after multivariable adjustment and in sensitivity analysis of patients with severe HF. Conclusions: Females had lower frequency of transfer to ATCs. In-hospital mortality and transfer rates to ATCs were similar across patient sex when adjusted for comorbidities and HF decompensations. Females consistently underwent fewer diagnostic and therapeutic interventions across all center types and transfers. Full article
(This article belongs to the Special Issue Clinical Challenges in Heart Failure Management: 2nd Edition)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

20 pages, 862 KB  
Review
Predicting Sudden Cardiac Death in Heart Failure with Mildly Reduced/Preserved Left Ventricular Ejection Fraction: A Clinical Review
by Mauro Feola, Federico Landra, Cosimo Angelo Greco, Roberto Lorusso and Gaetano Ruocco
J. Clin. Med. 2026, 15(8), 3041; https://doi.org/10.3390/jcm15083041 - 16 Apr 2026
Viewed by 457
Abstract
Cardiac arrest is a way of demise of patients who are affected by heart failure (HF), being more frequent in those with HF with a reduced left ventricular ejection fraction (HFrEF), and is, as such, responsible for 30–50% of cardiac death. Specific data [...] Read more.
Cardiac arrest is a way of demise of patients who are affected by heart failure (HF), being more frequent in those with HF with a reduced left ventricular ejection fraction (HFrEF), and is, as such, responsible for 30–50% of cardiac death. Specific data on the risk of sudden cardiac death (SCD) related to HF with a preserved ejection fraction (HFpEF) and HF with a mildly reduced ejection fraction (HFmrEF) are lacking, as well as data regarding ventricular arrhythmias in this population. Considering the 0.3% person/year incidence rate of investigator-reported ventricular tachycardia (VT) and ventricular fibrillation (VF), the rate of SCD in the analyzed population seems to be 1.3% per year. Age, gender, history of diabetes and myocardial infarction, left bundle branch block (LBBB) on electrocardiogram (ECG), and a natural logarithm of N-terminal pro B-type natriuretic peptide (NT-proBNP), identified a subgroup of HFpEF patients with a higher risk (5-year cumulative incidence of 11%) of sudden death (SD). In HFpEF patients, both glifozins and finerenone did not demonstrate a beneficial effect on SCD incidence in comparison to placebo. A significantly lower rate of SCD emerged in patients who were treated with dapaglifozin (10 vs. 26 pts) among patients with HF with an improved ejection fraction (HFimpEF), who were defined as patients with a previous left ventricular ejection fraction (LVEF) < 40%. Promising methods discussed include cardiac magnetic resonance, myocardial scintigraphy, genetic assessment, and electrophysiologic studies for predicting SCD in those patients. In conclusion, arrhythmic SCD in HFpEF patients should not be considered merely as an effect of VT/VF; bradyarrhythmia is probably more frequent and dangerous. The effects of drugs in preventing SCD in HFpEF have not been demonstrated yet. Full article
(This article belongs to the Special Issue Clinical Challenges in Heart Failure Management: 2nd Edition)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop